Photo of Shilpa Gupta taken from X/Twitter
Apr 8, 2024, 15:36
Shilpa Gupta: Happy to share our comprehensive review on adjuvant treatment of muscle-invasive urothelial cancer
Shilpa Gupta, Director of Genitourinary Oncology at Cleveland Clinic, shared on LinkedIn:
“Happy to share our comprehensive review on adjuvant treatment of muscle-invasive urothelial cancer!
A lot of progress has been made in MIBC with promising signals with ICI. (Checkmate 274, AMBASSADOR)
ctDNA appears to be a robust biomarker for patient selection. (IMvigor010)
Ongoing trial utilizing ctDNA for patient election will help advance the field further. (IMvigor011 and MODERN)
ICI not shown benefit in adjuvant UTUC, platinums remain kingpin.
Unmet need to learn from precision-oncology trials like PROOF302 (in FGFR3 select tumors).”
Source: Shilpa Gupta/LinkedIn
adjuvant treatment
AMBASSADOR trial
cancer
Checkmate 274 trial
Cleveland Clinic
ICI treatment
immune checkpoint inhibition
IMvigor010 trial
IMvigor011 trial
MIBC
MODERN trial
muscle-invasive urothelial cancer
OncoDaily
Oncology
PROOF302 trial
Shilpa Gupta
upper tract urothelial cancer
urothelial cancer